MENU

PRME Stock Prime Medicine (PRME, $3.68) was the month's biggest loser, descending -10.24%. Expect a Downtrend continuation

A.I.dvisor
at Tickeron.com
Loading...
PRME - Prime Medicine
Monthly drop
Bearish Trend
Odds of DOWN Trend
Tickeron

Loading...

Price: $3.68
Daily change: -$0.39 (-9.58%)
Daily volume: 6.6M
Monthly price change: -$0.42 (-10.24%)
Capitalization: $655.8M
Industry: Biotechnology
Prime Medicine (PRME, $3.68) was a top loser this month, diving -1 to $3.68 per share. Of the 790 stocks analyzed in the Biotechnology Industry throughout this month, of them (6) exhibited an Uptrend while of them (3) were in a Downtrend. A.I.dvisor found 302 similar cases when PRME's price dropped within one month. In out of those 302 cases, PRME's price continued to decline in the subsequent month. Based on this historical data, A.I. thinks the odds of a Downtrend continuation for PRME are

PRME's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Indicator for PRME moved out of overbought territory on July 15, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 instances where the indicator moved out of the overbought zone. In of the 8 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PRME as a result. In of 49 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PRME turned negative on July 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 26 similar instances when the indicator turned negative. In of the 26 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PRME broke above its upper Bollinger Band on July 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PRME advanced for three days, in of 130 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 46 cases where PRME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PRME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.086) is normal, around the industry mean (18.662). P/E Ratio (0.000) is within average values for comparable stocks, (54.033). PRME's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (97.087) is also within normal values, averaging (286.048).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. PRME showed earnings on August 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
21 Erie Street
Phone
+1 617 564-0013
Employees
234
Web
https://www.primemedicine.com